DB
RVMD icon

Dmitry Balyasny’s Revolution Medicines RVMD Stock Holding History

Dmitry Balyasny’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,799
Closed -$3.48M – 3431
2026
Q1 		$2.31M Sell
23,799
-391,408
-94% -$39.5M ﹤0.01% 1721
2025
Q4 		$33.1M Buy
415,207
+319,611
+334% +$21M 0.04% 498
2025
Q3 		$4.46M Buy
+95,596
New +$3.74M 0.01% 1417
2025
Q1 		– Sell
-1,302,848
Closed -$57M – 3222
2024
Q4 		$57M Sell
1,302,848
-348,957
-21% -$17.6M 0.08% 289
2024
Q3 		$74.9M Sell
1,651,805
-711,779
-30% -$31M 0.12% 181
2024
Q2 		$91.7M Buy
2,363,584
+708,689
+43% +$26.5M 0.16% 143
2024
Q1 		$53.3M Buy
1,654,895
+1,087,790
+192% +$32.2M 0.09% 282
2023
Q4 		$16.3M Sell
567,105
-395,552
-41% -$9.5M 0.03% 685
2023
Q3 		$26.6M Buy
+962,657
New +$28.6M 0.05% 476
2021
Q3 		– Sell
-75,137
Closed -$2.38M – 2362
2021
Q2 		$2.38M Sell
75,137
-44,915
-37% -$1.57M 0.01% 963
2021
Q1 		$5.51M Buy
+120,052
New +$5.38M 0.03% 665

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Dmitry Balyasny's RVMD Position: Q2 2026 in Review

Dmitry Balyasny sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 23,799 shares — an estimated $3.48M sold.

Dmitry Balyasny first reported a position in RVMD in Q1 2021 and held it in 11 quarters. The position peaked at $91.7M in Q2 2024. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Dmitry Balyasny reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 23,799 Revolution Medicines shares in Q2 2026, an estimated $3.48M.
  • Dmitry Balyasny first reported a position in Revolution Medicines in Q1 2021 and held it in 11 quarters.
  • Dmitry Balyasny's Revolution Medicines position peaked at $91.7M in Q2 2024.
  • 688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.